Published on 5/28/2010 in the Prospect News PIPE Daily.
New Issue: LaJolla Pharmaceuticals seals $6 million placement of preferreds, stock
By Devika Patel
Knoxville, Tenn., May 28 - LaJolla Pharmaceuticals Co. settled a $6 million private placement of its 15% series C-1 convertible preferred stock and common stock on Wednesday, according to an 8-K filed Friday with the Securities and Exchange Commission.
The company sold 5,134 preferreds at $1,000 apiece and 28,970,435 common shares at $0.03 per share. The preferreds are initially convertible into common stock at a rate of 66,667 shares per preferred.
Investors also received warrants for 10,268 units, exercisable at $1,000 per unit, that each consist of one 15% series C-2 preferred and an additional warrant for one series D-2 preferred.
The investors also received warrants to purchase 5,134 shares of series D-1 preferred stock at an exercise price of $1,000 per share.
All of the warrants are exercisable for three years.
Based in San Diego, LaJolla is a biotechnology company focused on developing therapeutics for antibody-mediated autoimmune diseases.
| Issuer: | LaJolla Pharmaceuticals Co.
|
| Issue: | Series C-1 convertible preferred stock, common stock
|
| Amount: | $6,003,113
|
| Warrants: | For 5,134 series D-1 preferreds, for 10,268 units of one 15% series C-2 preferred and an additional warrant for one series D-2 preferred
|
| Warrant expiration: | Three years
|
| Warrant strike price: | $1,000 (per unit)
|
| Settlement date: | May 26
|
| Stock symbol: | Pink Sheets: LJPC
|
| Stock price: | $0.06 at close May 24
|
| Market capitalization: | $3.61 million
|
|
|
| Series C-1 preferreds
|
| Amount: | $5,134,000
|
| Preferreds: | 5,134
|
| Price: | $1,000
|
| Dividends: | 15%
|
| Conversion rate: | 66,667 shares per preferred
|
|
|
| Common stock
|
| Amount: | $869,113
|
| Shares: | 28,970,435
|
| Price: | $0.03
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
